Pfizer is slated to present the results of the Phase III PALOMA-2 trial, a study designed to confirm the progression-free survival benefits experienced in patients treated with Ibrance (palbociclib) and the hormone therapy letrozole versus hormone therapy alone in the PALOMA-1 Phase II trial that resulted in FDA’s accelerated approval of the drug in early 2015.
ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition
Data to be presented at the American Society of Oncology meeting in June on cyclin-dependent kinase 4/6 inhibitors, an important new category of drugs to treat breast cancer, suggest Pfizer Inc. is well positioned to maintain its lead in the category even as new competition prepares to enter the market.